Why the study?
The diagnostic and prognostic usefulness of a single time point biomarker is limited, requiring combined and multi-time monitoring in cardiorenal syndrome.
Key points are not available for this paper at this time.
Design
Review
May support biomarker panels for renal risk assessment in cardiorenal syndrome; leaves open prospective validation before clinical adoption.
Cardiorenal syndrome is a clinical condition in which there is a correlation between heart and kidney diseases. In recent times, many biomarkers have been studied in patients with cardiovascular diseases for developing proper knowledge of renal function and identifying patients who are more susceptible to chronic or acute deterioration of renal function. Because diagnostic and prognostic usefulness of a single time point biomarker is limited, biomarkers should be combined and monitored at multiple times for optimal clinical impact. This review mainly lays emphasis on the potential clinical uses of the biomarkers in cardiorenal syndrome, recent advancements of biomarkers in developing therapeutic agents for Alzheimer’s disease, and classification of different types of biomarkers as well as highlights classic heart failure biomarkers with critical values adjusted to glomerular filtration rate and summarizes research progress of new heart failure biomarkers and future research directions.
No takes yet. Share an insight, caveat, or question.
Prajapati et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: